8th Janaushadhi Diwas Celebrated Across the Country with Enthusiastic Participation

1. At a Glance

2. Why in the News

3. Background & Evolution

4. Core Static Facts

5. Multi-Dimensional Analysis

Economic / Health Financing - Reduces out-of-pocket health expenditure (currently ~47% in India); generics at fraction of branded MRP cut household drug bills. [S3] - Cumulative savings to citizens estimated in thousands of crores; FY24 sales of Rs 1,000+ crore implies ~Rs 5,000+ crore notional savings. [S5]

Social / Equity - Expansion of 8,000+ women-run Kendras advances female entrepreneurship in tier-2/3 towns. [S2] - Coverage of 3,579 blocks across 406 districts in 26 States/UTs under fresh openings. [S6]

Administrative - Eligibility liberalised: individuals, pharmacists, NGOs, hospitals, SHGs can open Kendras with incentives up to Rs 5 lakh. [S3] - Quality assured via WHO-GMP certified suppliers and NABL-accredited lab testing. [S3]

Scientific / Industrial - Aligns with India's "Pharmacy of the World" positioning by promoting domestic generic manufacturers. [S3] - Strengthens National Pharmaceutical Pricing Authority (NPPA) objective of drug affordability. [S3]

6. Recent Developments (12-18 months)

7. Prelims Hooks

8. Mains Relevance

Possible stems: 1. "PMBJP has redefined affordability in India's healthcare landscape, but its impact remains uneven." Critically examine. 2. Discuss the role of generic medicines in reducing out-of-pocket health expenditure in India, with reference to PMBJP. 3. Evaluate the institutional architecture (PMBI, NPPA, CDSCO) supporting affordable medicines in India.

9. Related Topics to Study Next

10. Common Errors / Trap Areas

11. Sources